Cyclooxygenase-2 inhibitors: What went wrong?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 9, Issue 2, 2006, Pages 89-94

  James, Michael J ^a   Cleland, Leslie G ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Cardiovascular; Coxib; Cyclooxygenase 1; Cyclooxygenase 2; Non steroidal anti inflammatory drug

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DOXORUBICIN; FISH OIL; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOROLAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PARECOXIB; ROFECOXIB; VALDECOXIB;

ADENOMA; ADENOMATOUS POLYP; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIET SUPPLEMENTATION; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG INDUSTRY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; FOOT EDEMA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL TOXICITY; HEART DEATH; HEART INFARCTION; HUMAN; MEDICAL ETHICS; MEDICAL LITERATURE; NONHUMAN; OSTEOARTHRITIS; POSTOPERATIVE PAIN; REVIEW; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION; GASTROINTESTINAL DISEASES; HUMANS; RISK FACTORS;

EID: 33746232366     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000214565.67439.83     Document Type: Review

References (45)

1. Moncada S, Ferreira SH, Vane JR. Inhibition of prostaglandin biosynthesis as the mechanism of analgesia of aspirin-like drugs in the dog knee joint. Eur J Pharmacol 1975; 31:250-260.
2. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38:97-120.
3. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265:16737-16740.
4. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266:12866-12872.
5. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991; 266:23261-23267.
6. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69:145-182.
7. Lands WEM. Biosynthesis of prostaglandins. Annu Rev Nutr 1991; 11:41-60.
8. Kulmacz RJ. Cellular regulation of prostaglandin H synthase catalysis. FEBS Lett 1998; 430:154-157.
9. Laneuville O, Breuer DK, Xu N, et al. Fatty acid substrate specificities of human prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995; 270:19330-19336.
10. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384:644-648.
11. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96:7563-7568.
12. Patrono C, Patrignani P, Garcia-Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108:7-13.
13. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91:12013-12017.
14. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91:3228-3232.
15. Smith CJ, Zhang Y, Koboldt CM, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998; 95:13313-13318.
16. Caughey GE, Cleland LG, Penglis PS, et al. Roles of cyclooxygenase (COX)-1 and -2 in prostanoid production by human endothelial cells: selective upregulation of prostacyclin synthesis by COX-2. J Immunol 2001; 167:2831-2838.
17. 2. J Biol Chem 2001; 276:37839-37845.
18. Demasi M, Cleland LG, Cook-Johnson RJ, James MJ. Endothelial cell cyclooxygenase-2 expression and activity in hypoxia: interactions with human monocytes and implications for selective cyclooxygenase-2 inhibition. Arterioscler Thromb Vasc Biol 2004; 24:e52.
19. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289:735-741.
20. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96:272-277.
21. 2. Science 2002; 296:539-541.
22. Dowd NP, Scully M, Adderley SR, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001; 108:585-590.
23. Bolli R, Shinmura K, Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 2002; 55:506-519.
24. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353:307-314.
25. Juni P, Rutjes AWS, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? Br Med J 2002; 324:1287-1288.
26. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-1255.
27. FDA Advisory Committee Briefing Document. NDA 20-998/S-009: Celebrex Capsules (Celecoxib): Medical Officer Review 2000; http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3677b1 _03_med.doc.
28. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528.
29. FDA Advisory Committee Briefing Document. NDA 21-042, s007: VIOXX Gastrointestinal Safety 2001; http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3677b2_03_med.pdf.
30. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959.
31. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104:2280-2288.
32. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359:118-123.
33. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360:1071-1073.
34. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109:3000-3006. This case-control study using the UK General Practice Research Database found no relationship between acute myocardial infarction and use of non-selective NSAIDs, including naproxen.
35. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109:2068-2073. This case-control study using data from pharmaceutical benefits programmes in New Jersey and Pennsylvania found that rofecoxib at all prescribed doses (both including and above the common therapeutic dose of 25 mg) was associated with an increased risk of acute myocardial infarction compared with no NSAID use or with celecoxib.
36. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080. Full report of the APC trial that involved celecoxib and which was terminated early due to evidence of increased cardiovascular risk in the celecoxib group. These results were pivotal in forcing a re-examination by regulatory authorities of the cardiovascular warning with celecoxib use.
37. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102. Full report of the APPROVe trial that involved rofecoxib and which was terminated early due to evidence of increased cardiovascular risk in the rofecoxib group. These results were pivotal in the decision by Merck to withdraw rofecoxib from commercial use.
38. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081-1091.
39. Solomon DH. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 2005; 52:1968-1978. Review of cardiovascular safety data with coxibs.
40. James MJ, Cleland LG. Applying a research ethics committee approach to a medical practice controversy: the case of COX-2 inhibitors. J Med Ethics 2004; 30:182-184.
41. James MJ, Cleland LG. Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Semin Arthritis Rheum 1997; 27:85-97.
42. Cleland LG, James MJ, Proudman SM. The role of fish oils in the treatment of rheumatoid arthritis. Drugs 2003; 63:845-853.
43. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71 (Suppl):343S-348S.
44. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106:2747-2757.
45. Waxman HA. The lessons of Vioxx - drug safety and sales. N Engl J Med 2005; 352:2576-2578.